Literature DB >> 22659315

Determination of phospholipase activity of PAF acetylhydrolase.

Diana M Stafforini1, Thomas M McIntyre.   

Abstract

This article presents a radiometric assay to determine the enzymatic activity of platelet-activating factor (PAF) acetylhydrolase (PAF-AH), also known as lipoprotein-associated phospholipase A2 and phospholipase A2 group 7A. The method is based on the release of radioactively labeled acetate from sn-2-labeled PAF and separation of substrate and product using reversed-phase column chromatography on octadecyl silica gel cartridges. The assay is fast, convenient, reproducible, sensitive, and inexpensive. The instrumentation required includes standard laboratory equipment and a liquid scintillation counter. The assay is also useful to determine the activity of intracellular PAF-AH (PAF-AH II), provided that a few modifications are included. The enzymatic activity determined using PAF as the substrate is a direct indication of the ability of plasma samples, purified preparations, and cellular and tissue lysates to hydrolyze short- and medium-chain phospholipids that may or may not harbor oxidized functionalities. In addition, the assay can be used to test the suitability of other phospholipids, including species containing oxidized, long-chain sn-2 fatty acyl groups, as PAF-AH substrates. This versatile assay can be used to accurately determine PAF-AH activity in biological samples and preliminarily assess affinity and efficiency of the hydrolysis of potential substrates present in complex mixtures.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22659315      PMCID: PMC3444653          DOI: 10.1016/j.freeradbiomed.2012.05.031

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  57 in total

1.  Preparation of radioactive aldehyde-containing phosphatidylcholine.

Authors:  H Itabe; K Suzuki; R Hosoya; M Mori; Y Higashi; Y Fujimoto; T Takano
Journal:  Anal Biochem       Date:  2000-10-01       Impact factor: 3.365

2.  Spectrophotometric assay for serum platelet-activating factor acetylhydrolase activity.

Authors:  T Kosaka; M Yamaguchi; Y Soda; T Kishimoto; A Tago; M Toyosato; K Mizuno
Journal:  Clin Chim Acta       Date:  2000-06       Impact factor: 3.786

3.  Differential determination of phospholipase A(2) and PAF-acetylhydrolase in biological fluids using fluorescent substrates.

Authors:  E I Kitsiouli; G Nakos; M E Lekka
Journal:  J Lipid Res       Date:  1999-12       Impact factor: 5.922

Review 4.  Platelet-activating factor acetylhydrolase.

Authors:  Hiroyuki Arai
Journal:  Prostaglandins Other Lipid Mediat       Date:  2002-08       Impact factor: 3.072

Review 5.  Platelet-activating factor and related lipid mediators.

Authors:  S M Prescott; G A Zimmerman; D M Stafforini; T M McIntyre
Journal:  Annu Rev Biochem       Date:  2000       Impact factor: 23.643

6.  Lipoprotein associated phospholipase A2 concentration predicts total and cardiovascular mortality independently of established risk factors (The Ludwigshafen Risk and Cardiovascular Health Study).

Authors:  Marcus E Kleber; Robert L Wolfert; Graciela Delgado De Moissl; Tanja B Grammer; Simone Dietz; Bernhard R Winkelmann; Bernhard O Boehm; Winfried März
Journal:  Clin Lab       Date:  2011       Impact factor: 1.138

7.  Serum platelet-activating factor acetylhydrolase (PAF-AH) activity in more than 3000 healthy Japanese.

Authors:  T Kosaka; M Yamaguchi; K Miyanaga; K Mizuno
Journal:  Clin Chim Acta       Date:  2001-10       Impact factor: 3.786

8.  Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies.

Authors:  Alexander Thompson; Pei Gao; Lia Orfei; Sarah Watson; Emanuele Di Angelantonio; Stephen Kaptoge; Christie Ballantyne; Christopher P Cannon; Michael Criqui; Mary Cushman; Albert Hofman; Chris Packard; Simon G Thompson; Rory Collins; John Danesh
Journal:  Lancet       Date:  2010-05-01       Impact factor: 79.321

9.  Preliminary studies of an acid-labile factor (ALF) in human sera that inactivates platelet-activating factor (PAF).

Authors:  R S Farr; C P Cox; M L Wardlow; R Jorgensen
Journal:  Clin Immunol Immunopathol       Date:  1980-03

10.  Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project.

Authors:  Stefan Blankenberg; Tanja Zeller; Olli Saarela; Aki S Havulinna; Frank Kee; Hugh Tunstall-Pedoe; Kari Kuulasmaa; John Yarnell; Renate B Schnabel; Philipp S Wild; Thomas F Münzel; Karl J Lackner; Laurence Tiret; Alun Evans; Veikko Salomaa
Journal:  Circulation       Date:  2010-05-24       Impact factor: 29.690

View more
  4 in total

1.  Oligomeric state regulated trafficking of human platelet-activating factor acetylhydrolase type-II.

Authors:  Elizabeth S Monillas; Jeffrey L Caplan; Anastasia F Thévenin; Brian J Bahnson
Journal:  Biochim Biophys Acta       Date:  2015-02-20

2.  Characterization of streptococcal platelet-activating factor acetylhydrolase variants that are involved in innate immune evasion.

Authors:  Guanghui Liu; Mengyao Liu; Gang Xie; Benfang Lei
Journal:  Infect Immun       Date:  2013-06-17       Impact factor: 3.441

3.  Lp-PLA2, plaque inflammation and lesion development vary fundamentally between different vascular sites.

Authors:  Gunther Marsche
Journal:  J Am Heart Assoc       Date:  2015-02-11       Impact factor: 5.501

4.  High-Density Lipoprotein Function in Exudative Age-Related Macular Degeneration.

Authors:  Laura Pertl; Sabine Kern; Martin Weger; Silke Hausberger; Markus Trieb; Vanessa Gasser-Steiner; Anton Haas; Hubert Scharnagl; Akos Heinemann; Gunther Marsche
Journal:  PLoS One       Date:  2016-05-12       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.